Zelalem Temesgen, M.D.

  1. Infectious Disease Specialist
  1. Passerini M, Nayfeh T, Yetmar ZA, Coussement J, Goodlet KJ, Lebeaux D, Gori A, Mahmood M, Temesgen Z, Murad MH. Trimethoprim-sulfamethoxazole significantly reduces the risk of nocardiosis in solid organ transplant recipients: systematic review and individual patient data meta-analysis. Clin Microbiol Infect. 2024 Feb; 30 (2):170-177 Epub 2023 Oct 19
    View PubMed
  2. Rivera CG, Zeuli JD, Smith BL, Johnson TM, Bhatia R, Otto AO, Temesgen Z. HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic. Drugs. 2023 Dec; 83(18):1677-1698. Epub 2023 Dec 11.
    View PubMed
  3. Haile H, Tema L, Anjulo A, Temesgen Z, Jerene D. Pulmonary tuberculosis complicated by pneumothorax, and acute respiratory distress syndrome (ARDS) in the settings of advanced HIV disease: A case report. J Clin Tuberc Other Mycobact Dis. 2023 Dec; 33:100396 Epub 2023 Sept 04
    View PubMed
  4. Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schaferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velasquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. Lancet. 2023 Oct 21; 402 (10411):1473-1498 Epub 2023 Sept 13
    View PubMed
  5. Zeuli JD, Rivera CG, Wright JA, Kasten MJ, Mahmood M, Ragan AK, Rizza SA, Temesgen Z, Vergidis P, Wilson JW, Cummins NW. Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV. AIDS. 2023 Aug 1; 37 (10):1525-1533 Epub 2023 May 11
    View PubMed
  6. Marty PK, Yetmar ZA, Zhang Z, Temesgen Z, Nelson DR. Mediastinal Infection After Endobronchial Ultrasound-guided Transbronchial Needle Aspiration: An Uncommon Complication. J Bronchology Interv Pulmonol. 2023 Jul 1; 30 (3):307-310 Epub 2023 July 01
    View PubMed
  7. Temesgen Z, Kelley CF, Cerasoli F, Kilcoyne A, Chappell D, Durrant C, Ahmed O, Chappell G, Catterson V, Polk C, Badley A, Marconi VC, LIVE-AIR Study Group. C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial. Thorax. 2023 Jun; 78 (6):606-616 Epub 2022 July 06
    View PubMed
  8. Passerini M, Ratishvili T, Monroe JM, Temesgen Z, Witzig TE, Kay NE, Kennedy RB, Parikh SA. Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2023 Apr; 64 (4):874-883 Epub 2023 Mar 12
    View PubMed
  9. Cardenas MC, Farnan S, Hamel BL, Mejia Plazas MC, Sintim-Aboagye E, Littlefield DR, Behl S, Punia S, Enninga EAL, Johnson E, Temesgen Z, Theiler R, Gray CM, Chakraborty R. Prevention of the Vertical Transmission of HIV; A Recap of the Journey so Far. Viruses. 2023 Mar 26; 15 (4)
    View PubMed
  10. Zeuli JD, Rivera CG, Wright JA, Kasten MJ, Mahmood M, Ragan AK, Rizza SA, Temesgen Z, Vergidis P, Wilson JW, Cummins NW. Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV. AIDS (London, England). 2023; 37 (10):1525-33
  11. Passerini M, Maamari J, Geno Tai DB, Patel R, Tande AJ, Temesgen Z, Berbari EF. Cutibacterium acnes in spine tissue: characteristics and outcomes of non-hardware-associated vertebral osteomyelitis. J Bone Jt Infect. 2023; 8 (2):143-149 Epub 2023 Apr 25
    View PubMed
  12. Zeuli JD, Rivera CG, Smith BL, Otto A, Temesgen Z. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection. Drugs Today (Barc). 2022 Dec; 58 (12):555-576
    View PubMed
  13. Kalaiger AM, Assi M, Temesgen Z. Anti-gm-csf monoclonal antibody treatment of chronic myelomonocytic leukemia treatment of Covid-19. Drugs of the Future. 2022 Dec; 47 (12):887-92
  14. Drummond RA, Desai JV, Hsu AP, Oikonomou V, Vinh DC, Acklin JA, Abers MS, Walkiewicz MA, Anzick SL, Swamydas M, Vautier S, Natarajan M, Oler AJ, Yamanaka D, Mayer-Barber KD, Iwakura Y, Bianchi D, Driscoll B, Hauck K, Kline A, Viall NS, Zerbe CS, Ferre EM, Schmitt MM, DiMaggio T, Pittaluga S, Butman JA, Zelazny AM, Shea YR, Arias CA, Ashbaugh C, Mahmood M, Temesgen Z, Theofiles AG, Nigo M, Moudgal V, Bloch KC, Kelly SG, Whitworth MS, Rao G, Whitener CJ, Mafi N, Gea-Banacloche J, Kenyon LC, Miller WR, Boggian K, Gilbert A, Sincock M, Freeman AF, Bennett JE, Hasbun R, Mikelis CM, Kwon-Chung KJ, Belkaid Y, Brown GD, Lim JK, Kuhns DB, Holland SM, Lionakis MS. Human Dectin-1 deficiency impairs macrophage-mediated defense against phaeohyphomycosis. J Clin Invest. 2022 Nov 15; 132 (22)
    View PubMed
  15. Ghosh P, Nehra V, Temesgen Z. Furaprevir hcv ns3/4a protease inhibitor treatment of chronic hepatitis c virus infection. Drugs of the Future. 2022 Aug; 47 (8):557-65
  16. Temesgen Z, Burger CD, Baker J, Polk C, Libertin CR, Kelley CF, Marconi VC, Orenstein R, Catterson VM, Aronstein WS, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD, LIVE-AIR Study Group. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2022 Mar; 10 (3):237-246 Epub 2021 Dec 01
    View PubMed
  17. MacDonald DM, Collins G, Wendt CH, Wolfson J, Tracy RP, Rhame F, Deeks S, Rizza SA, Temesgen Z, Morse C, Liappis AP, Sereti I, Baker JV, Kunisaki KM. Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study. AIDS Res Hum Retroviruses. 2022 Feb; 38 (2):127-130 Epub 2021 Apr 30
    View PubMed
  18. Blumberg EA, Collins G, Young JH, Nguyen MH, Michonneau D, Temesgen Z, Origuen J, Barcan L, Obeid KM, Belloso WH, Gras J, Corbelli GM, Neaton JD, Lundgren J, Snydman DR, Molina JM, INSIGHT Clostridioides difficile Study Group. Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. Transpl Infect Dis. 2022 Feb; 24 (1):e13770 Epub 2021 Dec 13
    View PubMed
  19. Passerini M, Maamari J, Nayfeh T, Hassett LC, Tande AJ, Murad MH, Temesgen Z, Berbari EF. Early switch to oral antibiotic therapy for the treatment of patients with bacterial native vertebral osteomyelitis: a quaternary center experience, systematic review, and meta-analysis. J Bone Jt Infect. 2022; 7 (6):249-257 Epub 2022 Nov 23
    View PubMed
  20. Rivera CG, Otto AO, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs. Curr Opin HIV AIDS. 2021 Nov 1; 16 (6):279-285
    View PubMed
  21. Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU, Zeuli JD, Temesgen Z. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis. 2021 Aug; 24:100244 Epub 2021 May 08
    View PubMed
  22. Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data. Cells. 2021 May 20; 10 (5)
    View PubMed
  23. Koshy M, Mische L, Rizza S, Mahmood M, Bedimo R, Bhatia R, El Atrouni W, Curran J, Temesgen Z. Point-of-care program in HIV, tuberculosis, and associated conditions: A virtual global technical assistance platform to strengthen HIV and tuberculosis workforce capacity. J Clin Tuberc Other Mycobact Dis. 2021 May; 23:100238 Epub 2021 Apr 22
    View PubMed
  24. Wintheiser GA, Venable ER, Temesgen Z. Disseminated Nocardia in an Immunocompetent Host. Mayo Clin Proc. 2021 Apr; 96 (4):847-848
    View PubMed
  25. Baker JV, Wolfson J, Collins G, Morse C, Rhame F, Liappis AP, Rizza S, Temesgen Z, Mystakelis H, Deeks S, Neaton J, Schacker T, Sereti I, Tracy RP. Losartan to reduce inflammation and fibrosis endpoints in HIV disease. AIDS. 2021 Mar 15; 35 (4):575-583
    View PubMed
  26. Cano EJ, Fonseca Fuentes X, Corsini Campioli C, O'Horo JC, Abu Saleh O, Odeyemi Y, Yadav H, Temesgen Z. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2021 Mar; 159 (3):1019-1040 Epub 2020 Oct 28
    View PubMed
  27. O'Horo JC, Cerhan JR, Cahn EJ, Bauer PR, Temesgen Z, Ebbert J, Abril A, Abu Saleh OM, Assi M, Berbari EF, Bierle DM, Bosch W, Burger CD, Cano Cevallos EJ, Clements CM, Carmona Porquera EM, Castillo Almeida NE, Challener DW, Chesdachai S, Comba IY, Corsini Campioli CG, Crane SJ, Dababneh AS, Enzler MJ, Fadel HJ, Ganesh R, De Moraes AG, Go JR, Gordon JE, Gurram PR, Guru PK, Halverson EL, Harrison MF, Heaton HA, Hurt R, Kasten MJ, Lee AS, Levy ER, Libertin CR, Mallea JM, Marshall WF 3rd, Matcha G, Meehan AM, Franco PM, Morice WG 2nd, O'Brien JJ, Oeckler R, Ommen S, Oravec CP, Orenstein R, Ough NJ, Palraj R, Patel BM, Pureza VS, Pickering B, Phelan DM, Razonable RR, Rizza S, Sampathkumar P, Sanghavi DK, Sen A, Siegel JL, Singbartl K, Shah AS, Shweta F, Speicher LL, Suh G, Tabaja H Jr, Tande A, Ting HH, Tontz RC 3rd, Vaillant JJ, Vergidis P, Warsame MY, Yetmar ZA, Zomok CCD, Williams AW, Badley AD. Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. Mayo Clin Proc. 2021 Mar; 96 (3):601-618 Epub 2020 Dec 26
    View PubMed
  28. Sangarlangkarn A, Rizza SA, Mahmood M, Cummins NW, Temesgen Z. A National Survey of Provider's Preparedness to Care for Persons Living With HIV Aged >/=50 Years. J Contin Educ Health Prof. 2021 Jan 1; 41 (1):82-84
    View PubMed
  29. Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Palraj R, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley AD. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov; 95 (11):2382-2394 Epub 2020 Sept 03
    View PubMed
  30. Vallabhajosyula S, Subramaniam AV, Sundaragiri PR, Cheungpasitporn W, Temesgen Z, O'Horo JC, Jaffe AS, Barsness GW. Influence of Human Immunodeficiency Virus Infection on the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock. J Acquir Immune Defic Syndr. 2020 Nov 1; 85 (3):331-339
    View PubMed
  31. Temesgen ZM, DeSimone DC, Mahmood M, Libertin CR, Varatharaj Palraj BR, Berbari EF. Health Care After the COVID-19 Pandemic and the Influence of Telemedicine. Mayo Clin Proc. 2020 Sep; 95 (9S):S66-S68 Epub 2020 July 27
    View PubMed
  32. Temesgen Aelalam, Desimone Daniel, Mahmood Maryam, Libertin Claudia, Palra Bharath, Berbari Elie. Mayo Clinic Strategies for COVID-19 Health Care after the COVID-19 Pandemic and the Influence of Telemedicine Mayo Clinic Proceedings. 2020; 95(9):s66-s68. Epub 2020 Sep 01.
    View PubMed
  33. Temesgen Aelalam, Desimone Daniel, Mahmood Maryam, Libertin Claudia, Palra Bharath, Berbari Elie. Mayo Clinic Strategies for COVID-19 Health Care after the COVID-19 Pandemic and the Influence of Telemedicine Mayo Clinic Proceedings. 2020; 95(9):s66-s68. Epub 2020 Sep 01.
    View PubMed
  34. Wagner T, Shweta F, Murugadoss K, Awasthi S, Venkatakrishnan AJ, Bade S, Puranik A, Kang M, Pickering BW, O'Horo JC, Bauer PR, Razonable RR, Vergidis P, Temesgen Z, Rizza S, Mahmood M, Wilson WR, Challener D, Anand P, Liebers M, Doctor Z, Silvert E, Solomon H, Anand A, Barve R, Gores G, Williams AW, Morice WG 2nd, Halamka J, Badley A, Soundararajan V. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife. 2020 Jul 7; 9 Epub 2020 July 07
    View PubMed
  35. Berg M, Temesgen Z. Rovafovir etalafenamide nucleotide reverse transcriptase inhibitor treatment of hiv-1 infection Drugs of the Future. 2020 Jul; 45 (7):459-69
  36. Temesgen Z, Assi M, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Varatharaj Palraj BR, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley A. First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia. medRxiv 2020 Jun 14 Epub 2020 June 14
    View PubMed
  37. Fida M, Mahmood M, Temesgen Z. Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection. Drugs Today (Barc). 2020 Jun; 56 (6):405-421
    View PubMed
  38. Nehra V, Temesgen Z. Inarigivir soproxil. Retinoic acid-inducible gene I protein (RIG-I) activator, nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activator, treatment of chronic hepatitis b Drugs Of The Future. 2020 Apr; 45 (4):233-8
  39. Talwani R, Temesgen Z. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2020 Feb; 56 (2):113-124
    View PubMed
  40. Wyman Engen N, Huppler Hullsiek K, Belloso WH, Finley E, Hudson F, Denning E, Carey C, Pearson M, Kagan J, INSIGHT START Study Group. A randomized evaluation of on-site monitoring nested in a multinational randomized trial. Clin Trials. 2020 Feb; 17 (1):3-14 Epub 2019 Oct 24
    View PubMed
  41. Ghazi L, Baker JV, Sharma S, Jain MK, Palfreeman A, Necsoi C, Murray DD, Neaton JD, Drawz PE, INSIGHT START study group. Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. Am J Hypertens. 2020 Jan 1; 33 (1):43-52
    View PubMed
  42. Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, Barbosa de Souza M, Phillips AN, INSIGHT START Study Group. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS. 2019 Dec 1; 33 (15):2337-2350
    View PubMed
  43. Mase SR, Samron R, Ashkin D, Castro KG, Ryan S, Seaworth B, Chen L, Lardizabal A, Tuckey D, Khan A, Posey DL, Chappelle C, Temesgen Z. Tuberculosis Regional Training and Medical Consultation Centers in the United States: Characteristics, outcomes, and quality of medical consultations, June 1, 2010 - May 31, 2014. J Clin Tuberc Other Mycobact Dis. 2019 Dec; 17:100114 Epub 2019 July 02
    View PubMed
  44. Zeuli J, Rizza S, Bhatia R, Temesgen Z. Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov; 55 (11):669-682
    View PubMed
  45. Quan K, Rizza SA, Whitaker JA, Hernandez P, Davey RT Jr, Fernandez-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD, INSIGHT FLU-IVIG Study Group. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019 Nov; 7 (11):951-963 Epub 2019 Sept 30
    View PubMed
  46. Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, Sherman BT, Losso MH, Wood R, Paredes R, Molina JM, Helleberg M, Jina N, Kityo CM, Florence E, Polizzotto MN, Neaton JD, Lane HC, Lundgren JD, INSIGHT START study group . Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. J Infect Dis. 2019 Sep 13; 220 (8):1325-1334
    View PubMed
  47. Peterson RL, Vock DM, Babiker A, Powers JH 3rd, Hunsberger S, Angus B, Paez A, Neaton JD, INSIGHT FLU-IVIG study group. Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization. Contemp Clin Trials Commun. 2019 Sep; 15:100401 Epub 2019 June 21
    View PubMed
  48. Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Gimenez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernan MA, INSIGHT START Study Group and the HIV-CAUSAL Collaboration. Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. Am J Epidemiol. 2019 Aug 1; 188 (8):1569-1577
    View PubMed
  49. Sereti I, Gulick RM, Krishnan S, Migueles SA, Palfreeman A, Touzeau-Romer V, Belloso WH, Emery S, Law MG, INSIGHT START Study Group. ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. J Acquir Immune Defic Syndr. 2019 Aug 1; 81 (4):456-462
    View PubMed
  50. Bansi-Matharu L, Rodriguez Loria G, Cole SR, Mugerwa H, Vecino I, Lundgren J, Pulik P, Smith C, Phillips AN, INSIGHT START Study Group. Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators. AIDS. 2019 Jul 1; 33 (8):1385-1390
    View PubMed
  51. Sharma S, Schlusser KE, de la Torre P, Tambussi G, Draenert R, Pinto AN, Metcalf JA, Neaton JD, Laeyendecker O, INSIGHT START Study Group. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection. AIDS. 2019 Jul 1; 33 (8):1335-1344
    View PubMed
  52. Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Sharma S, Baker JV, Collins S, Mannheimer S, Pett S, Touzeau-Romer V, Polizzotto MN, Lundgren JD, Gardner EM, INSIGHT START Study Group. Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. J Int AIDS Soc. 2019 Jun; 22 (6):e25297
    View PubMed
  53. Fida M, Rizza SA, Temesgen Z. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy. Drugs Today (Barc). 2019 May; 55 (5):297-304
    View PubMed
  54. Berg M, Temesgen Z. Pimodivir polymerase basic protein 2 (pb2) (influenza virus) inhibitor treatment of influenza a infection Drugs Of The Future. 2019 May; 44 (5):339-48
  55. Bhatia R, El Atrouni W, Shweta FNU, Zeuli J, Rizza S, Temesgen Z. Update on hiv infection: a report from CROI 2019 Seattle, Washington, USA - March 4-7, 2019 Drugs Of The Future. 2019 May; 44 (5):385-96
  56. Boatman JA, Baker JV, Emery S, Furrer H, Mushatt DM, Sedlacek D, Lundgren JD, Neaton JD, INSIGHT START Study Group. Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. J Acquir Immune Defic Syndr. 2019 May 1; 81 (1):10-17
    View PubMed
  57. Holmberg PJ, Temesgen Z, Banerjee R. Tuberculosis in Children. Pediatr Rev. 2019 Apr; 40 (4):168-178
    View PubMed
  58. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet. 2019 Mar 30; 393 (10178):1331-1384 Epub 2019 Mar 20
    View PubMed
  59. Dharan NJ, Neuhaus J, Rockstroh JK, Peters L, Gordin F, Arenas-Pinto A, Emerson C, Marks K, Hidalgo J, Sarmento-Castro R, Stephan C, Kumarasamy N, Emery S, Matthews GV, INSIGHT START Study Group. Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology. 2019 Mar; 69 (3):1135-1150 Epub 2019 Feb 19
    View PubMed
  60. Borges AH, Neuhaus J, Sharma S, Neaton JD, Henry K, Anagnostou O, Staub T, Emery S, Lundgren JD, INSIGHT SMART//START Study Groups. The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. J Infect Dis. 2019 Jan 7; 219 (2):254-263
    View PubMed
  61. Rizza SA, Bhatia R, Zeuli J, Temesgen Z. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection. Drugs Today (Barc). 2019 Jan; 55 (1):25-34
    View PubMed
  62. Brummel-Ziedins KE, Gissel M, Neuhaus J, Borges ÁH, Chadwick DR, Emery S, Neaton JD, Tracy RP, Baker JV, ESPRIT study group. In silico thrombin generation: plasma composition imbalance and mortality in human immunodeficiency virus Res Pract Thromb Haemost. 2018; 2(4):708-717.
  63. Arenas-Pinto A, Grund B, Sharma S, Martinez E, Cummins N, Fox J, Klingman KL, Sedlacek D, Collins S, Flynn PM, Chasanov WM, Kedem E, Katlama C, Sierra-Madero J, Afonso C, Brouwers P, Cooper DA, INSIGHT START study group. Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial. Clin Infect Dis. 2018 Jul 18; 67 (3):420-429
    View PubMed
  64. Simonsen L, Higgs E, Taylor RJ, Wentworth D, Cozzi-Lepri A, Pett S, Dwyer DE, Davey R, Lynfield R, Losso M, Morales K, Glesby MJ, Weckx J, Carey D, Lane C, Lundgren J, INSIGHT FLU002 and FLU003 Study Groups. Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. Clin Infect Dis. 2018 Jul 18; 67 (3):341-349
    View PubMed
  65. Nehra V, Rizza SA, Temesgen Z. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults. Drugs Today (Barc). 2018 Jul; 54 (7):407-421
    View PubMed
  66. Dobler CC, Fox GJ, Douglas P, Viney KA, Ahmad Khan F, Temesgen Z, Marais BJ. Screening for tuberculosis in migrants and visitors from high-incidence settings: present and future perspectives. Eur Respir J. 2018 Jul; 52 (1) Epub 2018 July 11
    View PubMed
  67. Schlusser KE, Sharma S, de la Torre P, Tambussi G, Draenert R, Pinto AN, Metcalf JA, German D, Neaton JD, Laeyendecker O, INSIGHT START Study Group. Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial. AIDS Behav. 2018 Jul; 22 (7):2277-2283
    View PubMed
  68. Peterson TE, Huppler Hullsiek K, Wyman Engen N, Kumarasamy N, Lebech AM, Liappis A, Papadopoulos A, Polizzotto MN, Schreiner PJ, Duprez D, Baker JV, INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group. Inflammation Associates With Impaired Small Arterial Elasticity Early in HIV Disease. Open Forum Infect Dis. 2018 Jun 1; 5 (6):ofy117 Epub 2018 May 19
    View PubMed
  69. Rizza SA, Bhatia R, Temesgen Z. Novel HIV drugs and drug delivery strategies. A report from the 2018 Conference on Retroviruses and Opportunistic Infections Drugs of the Future 2018. 2018; 43(4):283-288.
  70. Rizza SA, Bhatia R, Temesgen Z. Novel hiv drugs and drug delivery strategies. a report from the 2018 conference on retroviruses and opportunistic infections Boston, Msachusetts, USA - March 4-7, 2018 Drugs Of The Future. 2018 Apr; 43 (4):283-8
  71. Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vanderkerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate iniation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial Lancet HIV. 2018; 5(4):e172-e180.
  72. Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group. Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. J Infect Dis. 2018 Jan 17; 217 (3):405-412
    View PubMed
  73. Brummel-Ziedins KE, Gissel M, Neuhaus J, Borges ÁH, Chadwick DR, Emery S, Neaton JD, Tracy RP, Baker JV, INSIGHT SMART Study Group, ESPRIT Study Group. Thrombin generation: plasma composition imbalance and mortality in HIV. Res Pract Thromb Haemost. 2018; 2(4):708-717.
  74. Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Collins S, Mannheimer S, Pett S, Touzeau-Römer V, Polizzotto MN, Lundgren JD, Gardner EM, INSIGHT SMART study group. Association of suboptimal antiretroviral therapy adherence with inflammation in virologically suppressed individuals enrolled in the SMART study. Open Forum Infect Dis. 2018; 5(1):ofx275.
  75. Hart BB, Nordell AD, Okulicz JF, Palfreeman A, Horban A, Kedem E, Neuhaus J, Jacobs DR Jr, Duprez DA, Neaton JD, INSIGHT, ESPRIT. Association of suboptimal antiretroviral therapy adherence with inflammation in virologically suppressed individuals? J Acquir Immune Defic Syndr. 2018; 77(1):1-7.
  76. Pett SL, Kunisaki KM, Wentworth D, Griffin TJ, Kalomenidis I, Nahra R, Montejano Sanchez R, Hodgson SW, Ruxrungtham K, Dwyer D, Davey RT, Wendt CH, INSIGHT FLU003 Plus Study Group. Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. Open Forum Infect Dis. 2018 Jan; 5 (1):ofx228 Epub 2017 Oct 25
    View PubMed
  77. Hart BB, Nordell AD, Okulicz JF, Palfreeman A, Horban A, Kedem E, Neuhaus J, Jacobs DR Jr, Duprez DA, Neaton JD, INSIGHT SMART and ESPRIT Groups. Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It? J Acquir Immune Defic Syndr. 2018 Jan 1; 77 (1):1-7
    View PubMed
  78. Go SA, Phuoc VH, Eichenberg SE, Temesgen Z, Beckman TJ. Babesia microti infection and hemophagocytic lymphohistiocytosis in an immunocompetent patient. Int J Infect Dis. 2017 Dec; 65:72-74 Epub 2017 Oct 06
    View PubMed
  79. Dwyer DE, Lynfield R, Losso MH, Davey RT, Cozzi-Lepri A, Wentworth D, Uyeki TM, Gordin F, Angus B, Qvist T, Emery S, Lundgren J, Neaton JD, INSIGHT Influenza Study Group. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. Open Forum Infect Dis. 2017 Fall; 4 (4):ofx212 Epub 2017 Oct 07
    View PubMed
  80. Achhra AC, Mocroft A, Ross M, Ryom-Nielson L, Avihingsanon A, Bakowska E, Belloso W, Clarke A, Furrer H, Lucas GM, Ristola M, Rassool M, Ross J, Somboonwit C, Sharma S, Wyatt C . Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial International Journal of Antimicrobial Agents. 2017; 50(3):453-60.
  81. Rizza SA, Nehra V, Temesgen Z. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children. Drugs Today (Barc). 2017 Aug; 53 (8):447-451
    View PubMed
  82. Peterson RL, Vock DM, Powers JH, Emery S, Cruz EF, Hunsberger S, Jain MK, Pett S, Neaton JD, INSIGHT FLU-IVIG Study Group. Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clin Trials. 2017 Jun; 14 (3):264-276 Epub 2017 Mar 06
    View PubMed
  83. Doshi R, Falzon D, Thomas BV, Temesgen Z, Sadasivan L, Migliori GB, Raviglione M. Tuberculosis control, and the where and why of artificial intelligence. ERJ Open Res. 2017 Apr; 3 (2) Epub 2017 June 21
    View PubMed
  84. Rizza SA, El Atrouni W, Bhatia R, Temesgen Z. Advances in HIV therapeutics. A report from the 2017 conference on retroviruses and opportunistic infections (CROI) Drugs Of The Future. 2017 Apr; 42: (4)241-9.
  85. Nehra V, Rizza SA, Temesgen Z. Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2017 Mar; 53 (3):177-189
    View PubMed
  86. Manyazewal T, Marinucci F, Belay G, Tesfaye A, Kebede A, Tadesse Y, Lehman S, Temesgen Z. Implementation and Evaluation of a Blended Learning Course on Tuberculosis for Front-Line Health Care Professionals. Am J Clin Pathol. 2017 Mar 1; 147 (3):285-291
    View PubMed
  87. Pande T, Saravu K, Temesgen Z, Seyoum A, Rai S, Rao R, Mahadev D, Pai M, Gagnon MP. Evaluating clinicians' user experience and acceptability of LearnTB, a smartphone application for tuberculosis in India. Mhealth. 2017; 3:30 Epub 2017 July 27
    View PubMed
  88. Sampath R, Zeuli J, Rizza S, Temesgen Z. Tenofovir alafenamide fumarate for the treatment of HIV infection. Drugs Today (Barc). 2016 Nov; 52 (11):617-625
    View PubMed
  89. Pichler M, Klaas J, Temesgen Z, Kantarci O. Clinical Reasoning: A 73-year-old man with sarcoidosis and multifocal ischemic strokes. Neurology. 2016 Sep 20; 87 (12):e119-23
    View PubMed
  90. Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi L, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC. Digital health for the End TB Strategy: developing priority products and making them work. Eur Respir J. 2016 Jul; 48 (1):29-45 Epub 2016 May 26
    View PubMed
  91. Cummins NW, Badley AD, Kasten MJ, Sampath R, Temesgen Z, Whitaker JA, Wilson JW, Yao JD, Zeuli J, Rizza SA. Twenty years of human immunodeficiency virus care at the Mayo Clinic: Past, present and future. World J Virol. 2016 May 12; 5 (2):63-7
    View PubMed
  92. Rizza SA, Cummins N, Hoffman-Therry M, Temesgen Z. 23rd conference on retroviruses and opportunistic infections (CROI 2016) Boston, Massachusetts, USA - February 22-25, 2016 Drugs Of The Future. 2016 Mar; 41: (3)203-12.
  93. INSIGHT FLU005 IVIG Pilot Study Group, INSIGHT FLU005 IVIG Pilot Study Group. INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. J Infect Dis. 2016 Feb 15; 213 (4):574-8 Epub 2015 Sept 15
    View PubMed
  94. Nehra V, Tan EM, Rizza SA, Temesgen Z. Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection. Drugs Today (Barc). 2016 Feb; 52: (2)111-7.
    View PubMed
  95. Walker RC, Zeuli JD, Temesgen Z. Isavuconazonium sulfate for the treatment of fungal infection. Drugs Today (Barc). 2016 Jan; 52: (1)7-16.
    View PubMed
  96. Tan EM, Lyle M, Cawcutt K, Temesgen Z. Poststernotomy Osteomyelitis Presenting with Severe Sepsis and Rhabdomyolysis. Case Rep Med. 2016; 2016:4507012 Epub 2016 Apr 10
    View PubMed
  97. Zeuli JD, Adie SK, Rizza SA, Temesgen Z. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2015 Nov; 51 (11):629-43
    View PubMed
  98. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fatkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD, INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27; 373 (9):795-807 Epub 2015 July 20
    View PubMed
  99. Achhra AC, Phillips A, Emery S, MacArthur RD, Furrer H, De S, Losso M, Law MG. Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy HIV Med. 2015; 16(7):449-454. Epub 2015 May 11.
  100. Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD, INSIGHT Study Group. Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine. 2015 Jul; 2 (7):706-12 Epub 2015 May 12
    View PubMed
  101. Rizza SA, Temesgen Z. Developments in the treatment of HIV and chronic hepatitis C virus infections - a report from CROI 2015 Seattle, Washington, USA - February 23-26, 2015. Drugs Future. 2015 May; 40(5):323-8.
  102. Temesgen Z, Rizza SA. Daclatasvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2015 May; 51 (5):277-88
    View PubMed
  103. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med doi 101111/hiv12227. 2015 Apr; 16 Suppl 1:1-9.
    View PubMed
  104. Baker JV, Engen NW, Huppler Hullsiek K, Stephan C, Jain MK, Munderi P, Pett S, Duprez D, for the INSIGHT START Study Group . Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial HIV Med. 2015; 16(Supplement 1):109-118.
  105. Achhra AC, Mocroft A, Ross JM, Ryom L, Lucas GM, INSIGHT Study Group. Kidney disease in antiretroviralnaive HIV-positive adults with high CD4: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of Antiretroviral Treatment trial HIV Med.2015;16:(S1):55-63.
  106. Béténé A Dooko C, De Wit S, Neuhaus J, Palfreeman A, Pepe R, Pankow JS, Neaton JD, for the INSIGHT SMART and ESPRIT Study Groups. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy J Aquir Immune Defic Syndr. 2014; 67(5):538-546.
  107. Peters L, Neuhaus J, Duprez D, Neaton JD, Tracy R, Klein MB, Mocroft A, Rockstroh J, Dore G, Lundgren JD, for the INSIGHT SMART study group . Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study J Clin Virol. 2014; 60:295-300.
  108. Temesgen Z, Talwani R, Rizza SA. Sofosbuvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2014 Jun; 50: (6)421-34.
    View PubMed
  109. Nordell AD McKenna M Borges ÁH Duprez D Neuhaus J Neaton JD, INSIGHT SMART ESPRIT Study Groups, SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc doi 101161/JAHA114000844. 2014 May 28; 3(3):e000844.
  110. Cummins NW, Neuhaus J, Sainski AM, Strausbauch MA, Wettstein PJ, Lewin SR, Plana M, Rizza SA, Temesgen Z, Touloumi G, Freiberg M, Neaton J, Badley AD, INSIGHT SMART Study Group. Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses. 2014 May; 30 (5):476-9 Epub 2014 Feb 14
    View PubMed
  111. Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD, for the INSIGHT SMART and ESPRIT study groups. Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy PLoS ONE. 2014; 9(4):e95061.
  112. Borges AH O'Connor JL Phillips AN Baker JV Vjecha MJ Losso MH Klinker H Lopardo G Williams I Lundgren JD, INSIGHT SMART Study Group, ESPRIT Study Group, SILCAAT Scientific Committee. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One doi 101371/journalpone0090978 eCollection 2014. 2014 Mar 13; 9(3):e90978.
  113. Dawood FZ, Roediger MP, Grandits G, Miller D, Fisher M, Zhang Z-M, Hodder S, Hoy JF, Lundgren JD, Neaton JD, Soliman EZ, INSIGHT SMART Study Group. Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy (SMART) Study J Electrocardiol. 2014; 47(2):264-271. Epub 2013 Dec 04.
  114. Lucas GM, Cozzi-Lepri A, Wyatt CM, Post FA, Bormann AM, Crum-Cianflone NF, Ross MJ, for the INSIGHT SMART Study Group. Glomerular filtration rate estimated using creatinine, cystatin C, or both markers and the risk of clinical events in HIV-infected individuals HIV Med. 2014; 15(2):116-123. Epub 2013 Sep 11.
  115. Jeffords J, Kane P, Moghaddam Y, Rucinski A, Temesgen Z. Exponentially disruptive innovation driven by service science and the Internet of Things as a Grand Challenge enabler in Education. Proceedings of 2014 International Conference on Interactive Collaborative Learning, ICL 2014. 2014; 1021-5.
  116. Rizza SA, Temesgen Z. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) Boston, Massachusetts, USA - March 3-6, 2014. Drugs Future. 2014; 39(4):309-16.
  117. Lynfield R, Davey R, Dwyer DE, Losso MH, Wentworth D, Cozzi-Lepri A, Herman-Lamin K, Cholewinska G, David D, Kuetter S, Ternesgen Z, Uyeki TM, Lane HC, Lundgren J, Neaton JD, INSIGHT Influenza Study Group. Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies. PLoS One. 2014; 9 (7):e101785 Epub 2014 July 08
    View PubMed
  118. Temesgen Z, Talwani R, Rizza SA. Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2014 Jan; 50 (1):7-14
    View PubMed
  119. Talwani R, Heil EL, Gilliam BL, Temesgen Z. Simeprevir: a macrocyclic HCV protease inhibitor. Drugs Today (Barc). 2013 Dec; 49: (12)769-79.
    View PubMed
  120. Saira K Lin X DePasse JV Halpin R Twaddle A Stockwell T Angus B Cozzi-Lepri A Delfino M Dugan V Dwyer DE Freiberg M Horban A Losso M Lynfield R Wentworth DN Holmes EC Davey R Wentworth DE Ghedin E, INSIGHT FLU002 Study Group, INSIGHT FLU003 Study Group. Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus. J Virol 2013 Jul doi 101128/JVI00240-13 Epub. 2013 May 15; 87(14):8064-74.
  121. Temesgen Z. Cobicistat, a pharmacoenhancer for HIV treatments. Drugs Today (Barc). 2013 Apr; 49 (4):233-7
    View PubMed
  122. Rizza SA, Cummins N, El Atrouni W, Badley AD, Dababneh A, Temesgen Z. Advances in the treatment of HIV and chronic hepatitis C virus infection: A report from the 20th conference on retroviruses and opportunistic infections (CROI 2013). Drugs Future. 2013; 38(5):325-33.
  123. Temesgen Z. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection. Drugs Today (Barc). 2012 Dec; 48 (12):765-71
    View PubMed
  124. Rizza SA, MacGowan RJ, Purcell DW, Branson BM, Temesgen Z. HIV screening in the health care setting: status, barriers, and potential solutions. Mayo Clin Proc. 2012 Sep; 87 (9):915-24
    View PubMed
  125. Talwani R, Gilliam BL, Rizza SA, Nehra V, Temesgen Z. Current status of treatment for chronic hepatitis C virus infection. Drugs Today (Barc). 2012 Mar; 48(3):219-31.
    View PubMed
  126. Gilliam BL, Patel D, Talwani R, Temesgen Z. HIV in Africa: Challenges and Directions for the Next Decade. Curr Infect Dis Rep. 2012 Feb; 14(1):91-101.
    View PubMed
  127. Kapelusznik L, Heil EL, Temesgen Z, Talwani R. Filibuvir: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection. Drugs Future. 2012; 37(11):767-75.
  128. Kapelusznik L, Heil EL, Temesgen Z, Talwani R. Setrobuvir: RNA-directed RNA polymerase inhibitor treatment of hepatitis C virus infection. Drugs Future. 2012; 37(10):725-33.
  129. Temesgen Z. Advances in antiretroviral and anti-hepatitis C virus infection therapy: A report from CROI 2012. Drugs Future. 2012; 37(5):369-74.
  130. Nehra V, Rizza SA, Talwani R, Temesgen Z. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection. Drugs Today (Barc). 2011 Nov; 47 (11):829-37
    View PubMed
  131. Rizza SA, Talwani R, Nehra V, Temesgen Z. Boceprevir. Drugs Today (Barc). 2011 Oct; 47: (10)743-51.
    View PubMed
  132. Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, Shlay JC, Somboonwit C, Reiss P, Stein JH, Neaton JD, INSIGHT SMART Study Group. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS. 2011 Jan 28; 25(3):367-77.
    View PubMed
  133. Temesgen Z. New drugs for HIV and hepatitis C virus infections: A report from CROI 2011. Drugs Future. 2011; 36(6):485-90.
  134. Pett SL Carey C Lin E Wentworth D Lazovski J Miró JM Gordin F Angus B Rodriguez-Barradas M Rubio R Tambussi G Cooper DA Emery S, INSIGHT-ESPRIT Study Group. Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Med 2011 Apr doi 101111/j1468-1293201000875x Epub. 2010 Aug 31; 12(4):219-27.
  135. Chahin N, Temesgen Z, Kurtin PJ, Spinner RJ, Dyck PJ. HIV lumbosacral radiculoplexus neuropathy mimicking lymphoma: diffuse infiltrative lymphocytosis syndrome (DILS) restricted to nerve? Muscle Nerve. 2010 Feb; 41 (2):276-82
    View PubMed
  136. Temesgen Z. Progress in the treatment of HIV infection: Based on data presented at the XVIII International AIDS Conference (July 18-23, 2010, Vienna). Drugs Future. 2010; 35(11):965-70.
  137. Temesgen Z. Developments in antiretroviral therapy based on data presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI) (February 16-19, 2010, San Francisco). Drugs Future. 2010; 35(5):437-42.
  138. Temesgen Z. PRO-140 humanized anti-CCR5 monoclonal antibody anti-HIV agent. Drugs Future. 2009 Oct; 34(10):789-92.
  139. Temesgen Z, Barreto J, Vento S. Micafungin - the newest echinocandin. Drugs Today (Barc). 2009 Jun; 45 (6):469-78
    View PubMed
  140. Temesgen Z. Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico. Expert Opin Investig Drugs. 2009 Apr; 18 (4):549-53
    View PubMed
  141. Mocroft A Wyatt C Szczech L Neuhaus J El-Sadr W Tracy R Kuller L Shlipak M Angus B Klinker H Ross M, INSIGHT SMART Study Group. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS. 2009; 23(1):71-82.
  142. Prevention. HIV Testing Implementation Guidance for Correctional Settings. January Available at: http://wwwcdcgov/hiv/topics/testing/resources/guidelines/correctional-settings. 2009 Jan; 2009 Jan:1-38.
  143. Temesgen Z. Advances in antiretroviral therapy: Data presented at the 16th Conference on Retroviruses and Opportunistic Infections. Drugs Future. 2009; 34(9):771-4.
  144. Wahner-Roedler DL, Welsh GA, Trusko BE, Froehling DA, Temesgen Z, Elkin PL. Using natural language processing for identification of pneumonia cases from clinical records of patients with serologically proven influenza. AMIA Annu Symp Proc. 2008 Nov 06; 1165.
    View PubMed
  145. Vento S, Cainelli F, Temesgen Z. Perspectives in therapy for hepatitis C. Expert Opin Investig Drugs. 2008 Nov; 17(11):1635-9.
    View PubMed
  146. Vento S, Cainelli F, Temesgen Z. Lung infections after cancer chemotherapy. Lancet Oncol. 2008 Oct; 9(10):982-92.
    View PubMed
  147. Hsue PY, Squires K, Bolger AF, Capili B, Mensah GA, Temesgen Z, Wanke CA, Wohl DA, Working Group 4. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation. 2008 Jul 8; 118(2):e41-7. Epub 2008 Jun 19.
    View PubMed
  148. Temesgen Z, Siraj DS. Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manag. 2008 Apr; 4 (2):493-500
    View PubMed
  149. Temesgen Z. Advances in antiretroviral therapy. Drug News Perspect. 2008 Mar; 21 (2):125-31
    View PubMed
  150. Ayo D, Temesgen Z. Mycobacterium Avium-Intracellulare. British Medical Journal Point of Care Reference. 2008.
  151. Temesgen Z. Primary care considerations in managing coronary artery disease in aging HIV-infected patients. Aging with HIV AAHIVM CME newsletter. 2008:5-9.
  152. Ferrari S, Toniolo A, Monaco S, Luciani F, Cainelli F, Baj A, Temesgen Z, Vento S. Viral Encephalitis: Etiology, Clinical Features, Diagnosis and Management. The Open Infectious Diseases Journal. 2008; 2:77-88.
  153. Carr AA Grund BB Neuhaus JB El-Sadr WM Grandits GB Gibert CD Prineas RJ, for the SMART Study Investigators. Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS. 2008; 22(2):257-267.
  154. Fox Z Phillips A Cohen C Baxter J Emery S Hirschel B Hullsiek KH Stephan C Lundgren J, SMART Study Group. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008; 22(17):2279-89.
  155. Elkin PL, Brown SH, Balas A, Temesgen Z, Wahner-Roedler D, Froehling D, Liebow M, Trusko B, Rosenbloom ST, Poland G. Biosurveillance evaluation of SNOMED CT's terminology (BEST Trial): coverage of chief complaints. Stud Health Technol Inform. 2008; 136:797-802.
    View PubMed
  156. Froehling DA, Elkin P, Wahner-Roedler D, Bauer BA, Temesgen Z. A case definition for human influenza for biosurveillance. AMIA Annu Symp Proc. 2008; 950. Epub 2008 Nov 06.
    View PubMed
  157. Knoll BM, Vento S, Temesgen Z. Etravirine. Drugs Today (Barc). 2008 Jan; 44 (1):23-33
    View PubMed
  158. Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol. 2007 Dec; 47(12):1570-9.
    View PubMed
  159. Knoll B, Lassmann B, Temesgen Z. Current status of HIV infection: a review for non-HIV-treating physicians. Int J Dermatol. 2007 Dec; 46(12):1219-28.
    View PubMed
  160. Fadel H, Temesgen Z. Maraviroc. Drugs Today (Barc). 2007 Nov; 43 (11):749-58
    View PubMed
  161. El-Atrouni WI, Temesgen Z. Darunavir. Drugs Today (Barc). 2007 Oct; 43: (10)671-9.
    View PubMed
  162. Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15; 45 (6):761-9 Epub 2007 Aug 07
    View PubMed
  163. Temesgen Z, Wohl DA, Altice FL. Coverage of the 14th Conference on Retroviruses and Opportunistic Infections (CROI). Infectious Diseases in Corrections Report April. 2007 Apr.
  164. Temesgen Z. Update on antiretroviral therapy. Drugs Fut. 2007; 32(5):469-476.
  165. Temesgen Z. Antiretroviral drugs in development: a report from HIV DART 2006. Drugs Future. 2007 Jan; 32(1):83-92.
  166. Temesgen Z. Interleukin-2 for the treatment of human immunodeficiency virus infection. Drugs Today (Barc). 2006 Dec; 42: (12)791-801.
    View PubMed
  167. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis. 2006 Oct 15; 43(8):1031-9. Epub 2006 Sep 13.
    View PubMed
  168. Temesgen Z. The latest in antiretroviral therapy. Drug News Perspect. 2006 Oct; 19 (8):491-8
    View PubMed
  169. Temesgen Z, Feinberg JE. Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor. Curr Opin Investig Drugs. 2006 Aug; 7(8):759-65.
    View PubMed
  170. Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SA, Vento S. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis. 2006 Aug; 6(8):496-507.
    View PubMed
  171. Temesgen Z, Warnke D, Kasten MJ. Current status of antiretroviral therapy. Expert Opin Pharmacother. 2006 Aug; 7 (12):1541-54
    View PubMed
  172. El-Atrouni W, Berbari E, Temesgen Z. HIV-associated opportunistic infections. Bacterial infections. J Med Liban. 2006 Apr-Jun; 54(2):80-3.
    View PubMed
  173. Yu A, Berbari E, Temesgen Z. Antiretroviral therapy in HIV. J Med Liban. 2006 Apr-Jun; 54(2):74-9.
    View PubMed
  174. Cainelli F, Temesgen Z, Vento S. HIV-associated malignancies. J Med Liban. 2006 Apr-Jun; 54(2):111-9.
    View PubMed
  175. Tsigrelis C, Berbari E, Temesgen Z. Viral opportunistic infections in HIV-infected adults. J Med Liban. 2006 Apr-Jun; 54(2):91-6.
    View PubMed
  176. Martinez J, Temesgen Z. Opportunistic infections in patients with HIV and AIDS. Fungal and parasitic infections. J Med Liban. 2006 Apr-Jun; 54(2):84-90.
    View PubMed
  177. Liang KP, Tleyjeh IM, Wilson WR, Roberts GD, Temesgen Z. Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans. J Clin Microbiol. 2006 Mar; 44 (3):892-8
    View PubMed
  178. Ferrari S, Vento S, Monaco S, Cavallaro T, Cainelli F, Rizzuto N, Temesgen Z. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc. 2006 Feb; 81(2):213-9.
    View PubMed
  179. Vento S, Cainelli F, Temesgen Z. Interleukin-2 therapy and CD4+ T cells in HIV-1 infection. Lancet. 2006 Jan 14; 367(9505):93-5.
    View PubMed
  180. Brown SH, Elkin PL, Bauer BA, Wahner-Roedler D, Husser CS, Temesgen Z, Hardenbrook SP, Fielstein EM, Rosenbloom ST. SNOMED CT: utility for a general medical evaluation template. AMIA Annu Symp Proc. 2006; 101-5.
    View PubMed
  181. Temesgen Z, Knappe-Langworthy JE, St Marie MM, Smith BA, Dierkhising RA. Comprehensive Health Enhancement Support System (CHESS) for people with HIV infection. AIDS Behav. 2006 Jan; 10(1):35-40.
    View PubMed
  182. Sagar S, Wilkinson JR, Erickson BJ, Temesgen Z, Boeve BF. Extensive S aureus spinal epidural empyema. Neurology. 2005 Dec 27; 65(12):1970.
    View PubMed
  183. Temesgen Z, Cainelli F, Vento S. Tipranavir. Drugs Today (Barc). 2005 Nov; 41 (11):711-20
    View PubMed
  184. Temesgen Z. [Bone and joint involvement in human immunodeficiency virus infection]. Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca. 2005; 72(3):177-82.
    View PubMed
  185. Temesgen Z, Beri G. HIV and drug allergy. Immunology & Allergy Clinics of North America. 2004 Aug; 24(3):521-31, viii.
    View PubMed
  186. Temesgen Z, Cainelli F, Warnke D, Koirala J, Collaborative Research Network (CORNET) Investigators. Initial antiretroviral therapy in chronically-infected HIV-positive adults. Expert Opin Pharmacother. 2004 Mar; 5 (3):595-612
    View PubMed
  187. Sampathkumar P, Temesgen Z, Smith TF, Thompson RL. SARS: epidemiology, clinical presentation, management, and infection control measures. Mayo Clin Proc. 2003 Jul; 78 (7):882-90
    View PubMed
  188. Vlahakis NE, Temesgen Z, Berbari EF, Steckelberg JM. Osteoarticular infection complicating enterococcal endocarditis. Mayo Clin Proc. 2003 May; 78(5):623-8.
    View PubMed
  189. Ten RM, Anderson PM, Zein NN, Temesgen Z, Clawson ML, Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol. 2002 Feb; 2 (2-3):333-44
    View PubMed
  190. Temesgen Z. Current status of antiretroviral therapies. Expert Opin Pharmacother. 2001 Aug; 2 (8):1239-46
    View PubMed
  191. Girard SE, Temesgen Z. Emerging concepts in disease management: a role for antimicrobial therapy in coronary artery disease. Expert Opin Pharmacother. 2001 May; 2 (5):765-72
    View PubMed
  192. Temesgen Z, Wright AJ. Antiretrovirals. Mayo Clin Proc. 1999 Dec; 74 (12):1284-301
    View PubMed
  193. Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Oliver L, Wright A, Oliver L, Wright A. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem. 1999 Sep; 45 (9):1465-76
    View PubMed
  194. Klein CJ, Dinapoli RP, Temesgen Z, Meyer FB. Central nervous system histoplasmosis mimicking a brain tumor: difficulties in diagnosis and treatment. Mayo Clin Proc. 1999 Aug; 74(8):803-7.
    View PubMed
  195. Temesgen Z. Overview of HIV infection. Ann Allergy Asthma Immunol. 1999 Jul; 83(1):1-5; quiz 6-7.
    View PubMed
  196. Norby SM, Bharucha AE, Larson MV, Temesgen Z. Acute pancreatitis associated with Cryptosporidium parvum enteritis in an immunocompetent man. Clin Infect Dis. 1998 Jul; 27 (1):223-4
    View PubMed
  197. Temesgen Z, Wright AJ. Recent advances in the management of human immunodeficiency virus infection. Mayo Clin Proc. 1997 Sep; 72 (9):854-8; quiz 859
    View PubMed
  198. Temesgen Z, Toal DR, Cockerill FR 3rd. Leclercia adecarboxylata infections: case report and review. Clin Infect Dis. 1997 Jul; 25 (1):79-81
    View PubMed
  199. Temesgen Z, Satoh K, Uhl JR, Kline BC, Cockerill FR 3rd. Use of polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) analysis to detect a point mutation in the catalase-peroxidase gene (katG) of Mycobacterium tuberculosis. Mol Cell Probes. 1997 Feb; 11(1):59-63.
    View PubMed
  200. Temesgen Z, Wright AJ. Current Advances in the Management of HIV Infection. Mayo Clin Proc. 1997; 27:854-9.
  201. Cockerill FR 3rd, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, Williams DL, Kline BC. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis. 1995 Jan; 171 (1):240-5
    View PubMed